The dean of the University of Oklahoma College of Public Health and a team of scientists worldwide have found a better way to prevent deadly blood clots after joint replacement surgery – a major problem that results in thousands of unnecessary deaths each year. The research appears this week in the New England Journal of Medicine.
The research team, which includes scientists from Oklahoma, Denmark, Australia and Canada, set out to find a better way to prevent blood clots without increasing the risk of bleeding. Blood clots, known as deep-vein thrombosis (DVT), affect the large veins in the lower leg and thigh. If the clot breaks free and moves through the bloodstream, it can lodge in the lungs, a condition known as pulmonary embolism (PE), which is often fatal. Pulmonary embolism is the most common preventable cause of sudden death after surgery.
Current preventive treatments include uncomfortable injections and one oral anti-clotting medicine that is difficult for patients and physicians to manage. Researchers wanted to find something better.
In a double-blind study of more than 3,000 patients, researchers tested a new type of anti-clotting drug called Apixaban, which is an oral medication. The medicine proved just as effective at preventing blood clots and reduced the risk of bleeding by half. Most importantly for patient convenience, it was much easier to use.
“This is a major step in our fight to prevent DVT and the many unnecessary deaths each year caused by blood clots after joint replacement surgery. We now have a better treatment that reduces the risk of bleeding, and a patient no longer has to endure injections by needle,” said Gary Raskob, Ph.D., a lead researcher on the project and dean of the OU College of Public Health.
Raskob, who is a renowned expert in the field, said as our population ages, the number of hip and knee replacements will skyrocket in the coming years, so an easier to use and safe preventive medicine is essential. According to the American Academy of Orthopaedic Surgeons, more than 700,000 primary total hip and knee replacements are performed each year in the United States, and that number is expected to grow to more than 3.5 million by 2030.
On average, 1 percent to 3 percent of people undergoing total joint replacement will end up with a symptomatic deep-vein thrombosis (blood clot in the legs) or a pulmonary embolism (a blood clot in the lungs).
Apixaban is now being studied in Phase III clinical trials and, if approved by the U.S. Food and Drug Administration, will be an important option for patients having joint replacement surgery.
Diane Clay | EurekAlert!
Using fragment-based approaches to discover new antibiotics
21.06.2018 | SLAS (Society for Laboratory Automation and Screening)
Scientists learn more about how gene linked to autism affects brain
19.06.2018 | Cincinnati Children's Hospital Medical Center
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
21.06.2018 | Earth Sciences
21.06.2018 | Life Sciences
21.06.2018 | Earth Sciences